Assessing the relation between coronary reflow and myocardial reflow.

No-Reflow Phenomenon in Central Retinal Artery Occlusion: Incidence, Risk Factors, and Clinical Implications. PLoS One (2015) 0.80

Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int (2015) 0.78

Predictors of no- reflow during primary angioplasty for acute myocardial infarction, from Medical College Hospital, Trivandrum. Indian Heart J (2017) 0.75

Early Administration of Intracoronary Nitroprusside Compared with Thrombus Aspiration in Myocardial Perfusion for Acute Myocardial Infarction: A 3-Year Clinical Follow-Up Study. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75

Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging (2017) 0.75

Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation (1992) 3.73

Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation (1996) 2.59

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation (1996) 2.31

Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction. Their relation to myocardial viability. Circulation (1995) 1.81

Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. Circulation (1991) 1.60

Time course of functional improvement in stunned myocardium in risk area in patients with reperfused anterior infarction. Circulation (1993) 1.59

Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol (1997) 1.28

Characterization of superoxide dismutases purified from either anaerobically maintained or aerated Bacteroides gingivalis. J Bacteriol (1990) 1.15

Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol (1999) 1.09

Spontaneous neoplastic lesions in aged Sprague-Dawley rats. Exp Anim (2001) 1.07

Pressure-derived collateral flow index as a parameter of microvascular dysfunction in acute myocardial infarction. J Am Coll Cardiol (2001) 0.99

Alpha 1-adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res (1987) 0.91

Alpha 1-adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation (1995) 0.89

Ultrasonic tissue characterization predicts myocardial viability in early stage of reperfused acute myocardial infarction. Circulation (1998) 0.86

Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol (1993) 0.86

Effects of phosphorylation of inhibitory GTP-binding protein by cyclic AMP-dependent protein kinase on its ADP-ribosylation by pertussis toxin, islet-activating protein. FEBS Lett (1988) 0.85

Effect of transferrin on the growth of Porphyromonas gingivalis. J Dent Res (1991) 0.84

Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion. Circulation (1991) 0.83

Prediction of wall motion recovery from the left anterior descending coronary artery velocity pattern recorded by transthoracic doppler echocardiography in patients with anterior wall myocardial infarction retrospective and prospective studies. Jpn Circ J (2001) 0.81

Beneficial effects of alpha 1-adrenoceptor activity on myocardial stunning in dogs. Circ Res (1991) 0.79

New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy: use of signal-averaged electrocardiography. Am Heart J (1993) 0.79

Beneficial effects of alpha 2-adrenoceptor activity on ischemic myocardium during coronary hypoperfusion in dogs. Circ Res (1989) 0.78

Alpha 2-adrenoceptor activity exerts dual control of coronary blood flow in canine coronary artery. Am J Physiol (1988) 0.77

Combination study of myocardial perfusion and left ventricular filling provides an excellent prediction of clinical outcomes in patients with reperfused myocardial infarction. Basic Res Cardiol (2006) 0.77

Role of alpha 1-adrenoceptor activity in progression of cardiac hypertrophy in guinea pig hearts with pressure overload. Cardiovasc Res (1989) 0.77

Temporal changes in regional end-diastolic wall thickness early after reperfusion in acute anterior myocardial infarction: relation to myocardial viability and vascular damage. Am Heart J (1996) 0.77

Alpha 2-adrenoceptor stimulation can augment coronary vasodilation maximally induced by adenosine in dogs. Am J Physiol (1989) 0.77

The role of Na+/H+ exchange in norepinephrine-induced protein synthesis in neonatal cultured rat cardiomyocytes. Jpn Circ J (1990) 0.76

An increase in myocardial beta-adrenoceptors to compensate for postischaemic dysfunction following coronary micro-embolisation in dogs. Cardiovasc Res (1989) 0.75

[Oral single-dose and 13-week repeat-dose toxicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in rats]. J Toxicol Sci (1997) 0.75

[A 13-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5-week recovery test]. J Toxicol Sci (1996) 0.75

[Renal toxicity of prulifloxacin (NM441) in rats]. J Toxicol Sci (1996) 0.75

Excretion of new quinolones and their glucuronide conjugates into human bile. Drugs (1995) 0.75

[A 13-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats followed by a 5-week recovery test]. J Toxicol Sci (1997) 0.75

[Toxicokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice and rats during 13-week dietary administration]. J Toxicol Sci (1997) 0.75

[A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test]. J Toxicol Sci (1996) 0.75

[A 26-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats followed by a 9-week recovery test]. J Toxicol Sci (1997) 0.75

Seventy-eight-week dietary carcinogenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. J Toxicol Sci (1997) 0.75

Enzyme-linked immunosorbent determination of the binding component to salivary glycoprotein from Streptococcus mitis ATCC 9811. J Osaka Univ Dent Sch (1987) 0.75

Incidence and time course of left ventricular dilation in the early convalescent stage of reperfused anterior wall acute myocardial infarction. Am J Cardiol (1994) 0.75

[Twenty-six-week intravenous toxicity study of montirelin hydrate (NS-3) in dogs followed by 9-week recovery test]. J Toxicol Sci (1995) 0.75

[Intraperitoneal single-dose toxicity studies of active metabolite, optical isomers, hydrolysis products and bi-product of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in mice]. J Toxicol Sci (1997) 0.75

[Single dose toxicity studies of metabolite, degradation product and impurity of montirelin hydrate (NS-3) in mice]. J Toxicol Sci (1995) 0.75

Substrate specificity of fucosyltransferase purified from human parotid saliva. J Dent Res (1987) 0.75

Role of increased alpha 1-adrenergic activity in cardiomyopathic Syrian hamster. Am J Physiol (1991) 0.75

Antecedent angina pectoris as a predictor of better functional and clinical outcomes in patients with an inferior wall acute myocardial infarction. Am J Cardiol (1999) 0.75

[Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats]. J Toxicol Sci (1996) 0.75

[Four-week intravenous toxicity study of montirelin hydrate (NS-3) in dogs followed by 4-week recovery test]. J Toxicol Sci (1995) 0.75

[The mechanism of increased thyroidal function caused by (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, administration in rats]. J Toxicol Sci (1997) 0.75

Beneficial effect of OPC-8212 (3,4-dihydro-6-(4-(3,4-dimethoxy benzoyl)-1-piperazinyl)-2(1H)-quinolinone on myocardial oxygen consumption in dogs with ischemic heart failure. Jpn Circ J (1986) 0.75

[A 13-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 5-week recovery test]. J Toxicol Sci (1997) 0.75

[A 12-month oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 2-month recovery test]. J Toxicol Sci (1997) 0.75

Effects of lithium ion on the inhibitory GTP-binding protein and its coupling response. Cell Signal (1991) 0.75

[A 13-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5-week recovery test]. J Toxicol Sci (1996) 0.75

[Single dose toxicity studies of montirelin hydrate(NS-3) in mice, rats and dogs]. J Toxicol Sci (1995) 0.75

[A case of hepatocellular carcinoma fed by the cystic artery treated with chemolipiodolization therapy]. Nihon Shokakibyo Gakkai Zasshi (2000) 0.75

[Single-dose toxicity studies of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in mice, rats and dogs]. J Toxicol Sci (1997) 0.75

[Five-week intravenous toxicity study of montirelin hydrate (NS-3) in rats followed by 4-week recovery test]. J Toxicol Sci (1995) 0.75

Adenosine-induced hyperemia attenuates myocardial ischemia in coronary microembolization in dogs. Am J Physiol (1989) 0.75

[Twenty-six-week intravenous toxicity study of montirelin hydrate (NS-3) in rats followed by 9-week recovery test]. J Toxicol Sci (1995) 0.75

[A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test]. J Toxicol Sci (1996) 0.75

[Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. J Toxicol Sci (1997) 0.75

[A 4-week intravenous toxicity study of the active metabolite (NM394) of prulifloxacin (NM441) in rats followed by a 4-week recovery test]. J Toxicol Sci (1996) 0.75

[Vascular irritability study of montirelin hydrate (NS-3) injection in rabbits]. J Toxicol Sci (1995) 0.75

Two-year dietary carcinogenicity study of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. J Toxicol Sci (1997) 0.75